Streetbeat News

Products Services

AFRI

Forafric Global PLC (NASDAQ:AFRI) has announced a 10-year renewable agreement to lease and operate a milling facility in Morocco, aiming to increase its milling capacity by 600 tons per day. This expansion, expected to commence in Q3 2024, is seen as a strategic move to enhance Forafric's operational footprint and crushing capacity with minimal capital investment. The agreement is pending regulatory approvals.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:42 pm

CYBN

Cybin Inc. (CYBN) announced updates on its clinical programs, including the expected initiation of a Phase 3 study for CYB003 in MDD by mid-2024 and Phase 2 results for CYB004 in GAD by Q4 2024. The company secured a $150 million funding round and received FDA Breakthrough Therapy Designation for CYB003. CYB003 showed promising Phase 2 results in MDD treatment, and CYB004 is in development for GAD, with a Phase 2 study underway. Cybin's intellectual property portfolio includes over 50 granted patents and 170 pending applications related to psychedelic-based treatments.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:42 pm

AU

Latin Metals Inc. has updated on its Organullo Project in Argentina, revealing results from an airborne magnetic and radiometric survey conducted by AngloGold Ashanti plc's subsidiary. The survey identified a high-priority structural corridor for drill testing. Under an existing agreement, AngloGold has the option to earn up to an 80% interest in the Organullo Project.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:40 pm

SVMH

SRIVARU Holding Limited (NASDAQ: SVMH, SVMHW) announced the completion of its PRANA 2.0 electric motorcycle's production model, following successful internal testing. The model, which boasts a 20% longer driving range of up to 250km on a single charge, has been submitted for final certification. The company has also established a complete supply network for the PRANA 2.0's production. CEO Mohanraj Ramasamy highlighted the milestone's significance and the company's focus on precision engineering, quality control, and strong strategic partnerships.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:39 pm

AIM

AIM ImmunoTech Inc. has successfully completed the cGMP manufacturing of 9,042 clinical vials of Ampligen, a product candidate for cancers, viral diseases, and immune disorders. This milestone is part of AIM's development and commercial strategy, with Ampligen being evaluated in various clinical trials for solid tumor treatments. The company emphasizes the importance of this achievement in seeking commercial partners and preparing for ongoing and upcoming trials.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:38 pm

MOBX

Mobix Labs, Inc. (NASDAQ:MOBX) has entered into a global distribution agreement with Arrow Electronics to focus on EMI Filtering products for the defense and aerospace markets. This partnership leverages Arrow's extensive distribution network and deep relationships in these sectors, aiming to increase Mobix Labs' visibility and customer base. Mobix Labs' products, which comply with various military standards, are already being used in significant U.S. military programs. The collaboration is seen as a strategic move to enhance Mobix Labs' growth in the defense and aerospace industries.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:36 pm

JAGX

The FDA has conditionally approved Jaguar Health's prescription drug Crofelemer for treating chemotherapy-induced diarrhea in dogs. Diarrhea is a leading cause for veterinary visits, with no FDA-approved anti-secretory agents available for treatment until now.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:35 pm

PLTR

'Undiscovered Gem' Palantir Technologies, Inc. (NYSE:PLTR) is anticipated to report a solid quarter ahead of its Q1 results, with a bullish analyst maintaining an Outperform rating and a $35 price target. The company is expected to report earnings of 8 cents per share on revenue of $625.33 million, up from last year's earnings of 5 cents per share and revenue of $525.19 million. Analyst Daniel Ives from Wedbush predicts strong performance, particularly from the U.S. commercial segment, and highlights Palantir's potential to capitalize on the AI revolution and commercial spending tailwinds. Ives also expects Palantir to gain a significant share of the $1 trillion global AI market, with the U.S. commercial business projected to grow by at least 40% in 2024.

Portfolio Pulse from Shanthi Rexaline

May 06, 2024 | 12:35 pm

TCBP

TC BioPharm (NASDAQ:TCBP) announced its second non-binding letter of intent in recent months to acquire a biotech company focused on CAR-T therapies for cancer. This move aligns with TCBP's M&A strategy to enhance its allogeneic gamma-delta T cell therapy platform. The acquisition target has demonstrated proof of concept for its CAR-T therapies against solid tumors and is developing treatments for autoimmune diseases. The completion of this acquisition is contingent on several factors, including financing and regulatory approvals.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:34 pm

NRXP

NRx Pharmaceuticals announced the final results of its clinical trial, indicating that its drug NRX-101 has shown to reduce akathisia while maintaining comparable antidepressant efficacy. The company believes these results may constitute a basis for seeking accelerated FDA approval for NRX-101.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:34 pm